Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.60 |
| ▸ | ANPEP | P15144 | 3/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 5/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Iv SCHEMBL4322224 | 0.93 | LNPEP (0.68) | LNPEPANPEPAGTR1AGTR2REN | |
| Angiotensin Iv SCHEMBL4322236 | 0.93 | LNPEP (0.68) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL13081986 | 0.92 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL29701255 | 0.90 | SLC6A2 (0.63) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL9010597 | 0.90 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL9010601 | 0.90 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL4756875 | 0.89 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL4757555 | 0.89 | LNPEP (0.56) | LNPEPANPEPRENSLC6A2F2 | |
| SCHEMBL29619755 | 0.88 | LNPEP (0.63) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL4756901 | 0.88 | LNPEP (0.61) | LNPEPANPEPAGTR1AGTR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | IAPP, ANPEP, ENPEP | LNPEP 12/4885ANPEP 2/4885AGTR1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.